Schizophrenia Clinical Trial
Official title:
Characteristics of Prepulse Inhibition (PPI) of Startle Reflex in Patients With Schizophrenia in Relation to Type of Pharmacological Treatment and Duration of Illness
PPI is an objective measure to assess pre-attentive processes that have already been tested
before in the case of schizophrenia. The investigators aim to assess through this instrument
two main characteristics, that the investigators assume are of relevance which are the
duration of illness and the type of pharmaceutical treatment, patients receive.
The investigators believe these two main characteristics are critical to the ability of the
patients in improvement of their PPI response to startle reflex.
It is common to relate changes of PPI to startle reflex to both negative and positive signs
of schizophrenia. Results can both start to explain formations of delusions and
hallucinations and the difficulty in processing information for surrounding. It was already
tested and discussed in previous trials the relation between type of pharmaceutical treatment
as affecting on PPI to startle reflex both causing changes, or improving previous results.
In previous trials as opposed to our planned trial, not much attention was paid for the
relation on the changes found to the type of treatment and the duration of the illness. Plus,
most trails had different methods of assessing it than our method.
The investigators assume that patients who are receiving typical antipsychotic treatment
would have a reduced PPI response to startle reflex compared with those with atypical
antipsychotic treatment and those with longer duration of illness would also have reduced PPI
response to startle reflex in comparison to those with shorted duration of illness.
The investigators aim to enroll patients already diagnosed with schizophrenia that would be
sent by their psychiatrist to the trial. In addition the investigators would enroll control
group, not diagnosed with any psychiatric condition.
For both groups, the investigators would run PPI trials according to a unified protocol.
In addition the investigators would run several questionnaires for the group of the patients.
Among the details asked of the patient are the duration of the illness and the type of
antipsychotic medications they are on and the dosage. Data will then be analyzed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |